Hints and tips:
...Shares in Vectura, whose clients include GlaxoSmithKline and Hikma Pharmaceuticals, closed up 14 per cent at 155p....
...“I feel very strongly that we should get as many shots in arms as possible, right away,” Mr Gottlieb told USA Today last week. “The reality is that one dose is partially protective....
...In particular, WBA pointed to a 2.3 per cent year-on-year rise in sales at its main Retail Pharmacy USA division, with a rise in pharmacy sales offsetting declining retail sales....
...In September last year, Novartis said it would sell parts of the Sandoz US business to Aurobindo Pharma USA to focus on “higher growth areas”....
...Two types of chemotherapy, known as vincristine and etoposide, are in short supply, according to several hospitals, as drugmakers including Pfizer and London-listed Hikma Pharmaceuticals struggle to meet...
...On Thursday, Novartis said it would sell portions of the Sandoz US portfolio to Aurobindo Pharma USA in order to focus on “higher growth areas”....
...“Anyone with the appetite and dollars to buy can, whether it’s a Patrick Soon-Shiong [the pharmaceuticals billionaire who owns the LA Times] or an Alden.”...
...Some pharmaceutical groups implemented much larger increases....
...Hikma Pharmaceuticals fell on Thursday after it lowered its guidance for 2017 generics sales and warned its group revenues will come in at the low end of the forecast it issued in May amid an “increasingly...
...The companies now under investigation are: Heritage Pharmaceuticals, Inc.; Aurobindo Pharma USA, Inc.; Citron Pharma, LLC; Mayne Pharma (USA), Inc.; Mylan Pharmaceuticals, Inc.; Teva Pharmaceuticals USA;...
...(Nature) Food allergies An overview of pharmaceutical issues for healthcare professionals dealing with allergies and intolerances, from coeliac disease to lactose intolerance, shellfish and e-numbers....
...Mass drug administration, supported by donations from a dozen pharmaceutical groups, plays an important part in this success. Fresh innovation is needed to produce better medicines and diagnostics....
...Taking the podium alongside Mr Gou at the White House, President Trump said it was a “great day” for “everyone who believes in Made in the USA” and claimed personal credit for Mr Gou’s investment....
...Mr Schneider’s background in healthcare suggests he will seek growth opportunities for Nestlé’s fledgling “health science” division, which is pushing the group closer towards a pharmaceuticals business....
...The corporate calendar for Wednesday includes E.On, Hikma Pharmaceuticals, Polymetal International and Robert Walters....
...Said Darwazah, Chairman and Chief Executive Officer of Hikma, said: We have taken important strategic steps this year....
...Shareholders are taking a dim view of the gloomier assessment by Hikma Pharmaceutical of Roxane Laboratories, which it agreed to buy last year....
...Shares in Hikma Pharmaceuticals have taken a dive after it sliced $535m off its offer price for generic medicines business Roxane Laboratories and said it was expecting lower revenues from its acquisition...
...Mr Soon-Shiong, 63, is a surgeon and scientist, known for pioneering diabetes and cancer therapies and has founded a number of pharmaceuticals companies, including American Pharmaceutical Partners and Abraxis...
...A California billionaire who has long coveted the Los Angeles Times has acquired a 13 per cent stake in Tribune Publishing, its parent company, which is being stalked by rival Gannett, the owner of USA Today...
...As head of the firm’s M&A practice, Mr Cooke recently led the team advising Hikma Pharmaceuticals on its $2.65bn acquisition of Roxane from Boehringer Ingelheim, and Shire on its proposed merger with AbbVie...
...The results added pressure on Mr Ferro to negotiate with Gannett, owner of USA Today, which has offered to buy the smaller newspaper publisher for $15 a share — double the value of its stock price two months...
...Lower down the drugs chain, Jordan-based Hikma Pharmaceuticals enjoyed second place on the mid-cap FTSE 250 index, rising 3 per cent to £17.42, after falling more than 6 per cent in the previous session...
...The Jordan-based pharmaceutical group underlined its appetite for acquisitions with the $21m purchase of an Egyptian rival....
International Edition